Advice
Following a full submission
rivaroxaban (Xarelto®) is accepted for use within NHS Scotland for the prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery.
In three large phase III studies in patients undergoing either total knee or total hip replacement surgery, rivaroxaban was superior to low molecular weight heparin in reducing the incidence of VTE and all cause mortality with patients while having a similar incidence of major bleeding events.
Download detailed advice70KB (PDF)
Medicine details
- Medicine name:
- rivaroxaban (Xarelto)
- SMC ID:
- 519/08
- Indication:
- Prevention of VTE in elective hip or knee replacement surgery
- Pharmaceutical company
- Bayer plc/Bayer Schering Pharma
- BNF chapter
- Cardiovascular system
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 08 December 2008